Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Deficiencia de G6PD: kit de determinación cuantitativa de la actividad de glucosa-6-fosfato deshidrogenasa en la sangre

Resumen

Tipo:
Oferta Tecnológica
Referencia:
09 IT 55Y2 3FF9
Publicado:
19/06/2015
Caducidad:
20/12/2015
Resumen:
Una pyme italiana perteneciente a los sectores de biomedicina y veterinaria ha desarrollado un kit de determinación cuantitativa de G6PD (glucosa-6-fosfato deshidrogenasa) en la sangre. La deficiencia de glucosa-6-fosfato deshidrogenasa es un defecto enzimático hereditario que afecta a 200 millones de personas en todo el mundo y se manifiesta por crisis hemolíticas causadas por la ingestión de habas o medicamentos o por infecciones virales o bacterianas. El kit ha sido validado en instrumentos automáticos con una longitud de onda de 540 nm y 340 nm. La empresa está interesada en establecer acuerdos comerciales con asistencia técnica.

Details

Tittle:
Kit for quantitative determination of Glucose-6-Phosphate Dehydrogenase activity on whole blood
Summary:
An Italian SME, operating in the biomedical and veterinarian sector, has developed a kit for quantitative determination of G6PD activity on whole blood (Glucose-6-Phosphate Dehydrogenase). Kinetic, ultraviolet assay of G6PD activity is available on discrete analyzers. The SME is looking for a commercial agreement with technical assistance.
Description:
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an hereditary enzymatic defect that affects over 200 million people all over the world: the main clinical manifestation is that of hemolytic crises caused either by ingestion of fava beans or certain drugs, or by viral or bacterial infections. The enzyme deficiency is transmitted as an X-linked gene: males are more likely to be affected by this deficiency than females, as they can be either homozygote or heterozygote for the defect.
G6PD activity is calculated on NADPH absorbance values (nicotinamide adenine dinucleotide phosphate-oxidase) at 340nm in the course of the reaction. The results are expressed in terms of enzyme units (µmoles of substrate converted/min.) per gram of hemoglobin.
Hemoglobin concentration is measured by Drabkin's solution in the same hemolysate used for G6PD assay.

Advantages and Innovations:

The Glucose-6-phosphate dehydrogenase (G6PD) kit was validated on totally automatic instruments that work at a wavelength of 540nm and 340nm.

Innovations and advantages, which a centre of research or an SME could find interesting to develop:
- Discrete analyzer applications;
- Assay recommended by WHO;
- Short time to perform assays;
- Highly reproducible results;
- The kit is ready-to-use reagents for G6PD and Healthy Beginnings evaluation.
Stage of Development:
Field tested/evaluated
IPs:
Secret know-how

Partner sought

Type and Role of Partner Sought:
- Type of partner sought:
* Diagnostics company
* Public and privaty clinical laboratory
* Academy, research organisation

- Specific area of activity of the partner: Molecular diagnostics, clinical pathology, microbiology

- Task to be performed by the partner sought: technical consultancy.
Type of Partnership Considered:
Joint Venture Agreement
Technical consultancy

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis